News & Updates
Showing Oncology articles
Showing
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
In the planned final overall survival (OS) analysis of the FLAURA2 trial, first-line (1L) osimertinib plus chemotherapy significantly improved OS compared with osimertinib alone in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), supporting osimertinib as the backbone treatment in this setting.
Half of patients with EGFRm NSCLC on osimertinib-chemo alive at 4 years in FLAURA2
29 Sep 2025
Oral methylcobalamin eases hand-foot syndrome in breast cancer patients
The use of oral methylcobalamin is effective in lessening the severity of hand-foot syndrome, without any serious safety concerns, among women with HER2 negative early breast cancer who are treated with adjuvant capecitabine, a study has shown.
Oral methylcobalamin eases hand-foot syndrome in breast cancer patients
26 Sep 2025
Should PPIs be avoided in mHSPC patients treated with upfront docetaxel?
A landmark analysis of data from a Hong Kong prostate cancer database found that use of proton-pump inhibitors (PPIs) was associated with inferior oncological outcomes in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who received upfront docetaxel.